- Home
- EDTK vs ICU Comparison
EDTK vs ICU Comparison
Compare EDTK & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | ICU |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7M | 15.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDTK | ICU |
|---|---|---|
| Price | $1.00 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.7K | ★ 2.2M |
| Earning Date | 01-14-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $893,690.00 | $881,000.00 |
| Revenue This Year | N/A | $691.85 |
| Revenue Next Year | N/A | $64.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1195.59 |
| 52 Week Low | $0.80 | $0.29 |
| 52 Week High | $1.20 | $3.07 |
Technical Indicators
Market Signals| Indicator | EDTK | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 40.22 |
| Support Level | $0.97 | $0.30 |
| Resistance Level | $1.06 | $0.35 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 42.28 | 65.94 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.